WILMINGTON, Del. Jan 19 Pfizer Inc (PFE.N)
asked a U.S. federal court to block Teva Pharmaceutical
Industries Ltd (TEVA.TA)TEVA.O from selling a generic form of
its Zyvox antibiotic that it said would infringe a patent,
according to court documents.
New York-based Pfizer asked the court for an injunction to
prevent Israel's Teva from making or selling a generic version
of Zyvox, according to the complaint filed on Friday in U.S.
District Court in Delaware.
Zyvox, which is used to treat pneumonia and skin
infections, has annual global sales of about $1.1 billion. The
Teva generic would threaten Zyvox's U.S. sales, which totaled
about $575 million.
Teva filed an abbreviated new drug application with the
U.S. Food and Drug Administration, seeking approval to sell a
generic version of Zyvox. Pfizer said the move infringed its
Pfizer said in the complaint that its Zyvox patent would
not expire until at least 2014.
Teva declined to comment.
Shares of Pfizer were up 2 percent at $19.89 in morning
trading, while U.S.-traded shares of Teva rose 0.4 percent to
The case is Pfizer Inc. et al v. Teva Parenteral Medicines
Inc. et al, U.S. District Court, District of Delaware, No.
(Reporting by Tom Hals; Editing by Lisa Von Ahn)